Belite Bio, Inc (BLTE): Price and Financial Metrics Recent IPO


Belite Bio, Inc (BLTE): $28.22

-1.80 (-6.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLTE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BLTE Stock Price Chart Interactive Chart >

Price chart for BLTE

BLTE Price/Volume Stats

Current price $28.22 52-week high $44.70
Prev. close $30.02 52-week low $8.80
Day low $28.00 Volume 53,125
Day high $31.84 Avg. volume 259,177
50-day MA $30.94 Dividend yield N/A
200-day MA $0.00 Market Cap 701.75M

Belite Bio, Inc (BLTE) Company Bio


Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.


BLTE Latest News Stream


Event/Time News Detail
Loading, please wait...

BLTE Latest Social Stream


Loading social stream, please wait...

View Full BLTE Social Stream

BLTE Price Returns

1-mo -34.34%
3-mo 109.04%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4359 seconds.